. 2017 Aug 29;38(5):2031–2039. doi: 10.1007/s10792-017-0695-z

Table 2.

Results of switching from ranibizumab to bevacizumab

Study	Sample size (eyes)	Reason for switch	FU duration	Outcome (mean change)
Aslankurt et al. [12]	20	Cost and general health insurance applications	19.7 ± 9.4 months	VA	Improved (−0.03 logMAR)
Aslankurt et al. [12]	20	Cost and general health insurance applications	19.7 ± 9.4 months	CMT	No change (−1 μm)
Ehlken et al. [13]	24	Unresponsiveness to treatment (no improvement or deterioration in VA and morphology)	3 months	VA	No change* (actual value not reported)
Ehlken et al. [13]	24		3 months	CFT	Decreased (−28 μm)
Gasperini et al. [10]	16	Poor response to treatment (lack of definite reduction or an increase in exudation in any compartment)	13 months	VA	Improved (actual value not reported)
				SRF	Decreased (actual value not reported)
				CME
				PED
Pinheiro-Costa et al. [19]	110	Pharmacoeconomic nonmedical board decision	12.2 ± 2.6 months	VA	Decreased* (−2.4 letters)
Pinheiro-Costa et al. [19]	110	Pharmacoeconomic nonmedical board decision	12.2 ± 2.6 months	CRT	Increased (+19.1 μm)

* p value ≤ 0.05